PMC5109712_01
Baseline and repeat FDG-PET/CT scan illustrating areas of FDG uptake. Legend: a, b and c Baseline FDG-PET/CT scan revealed hypermetabolic activity consistent with metastatic disease. d, e and f Repeat FDG-PET/CT scan following cycle 5 of nivolumab demonstrated significant decrease in size and FDG uptake of all sites of disease
40425_2016_186_Fig1_HTML.jpg
PMC5109712_01_40425_2016_186_Fig1_HTML.jpg
Fig1
Staging fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) revealed lesions in right upper lung, right upper back, right axilla and right adrenal gland consistent with metastatic disease (Fig. 1a, b and c). After five cycles, he achieved a marked partial metabolic response by FDG-PET/CT (Fig. 1d, e and f).